CA2974775C - Biomarkers for pancreatic cancer - Google Patents

Biomarkers for pancreatic cancer Download PDF

Info

Publication number
CA2974775C
CA2974775C CA2974775A CA2974775A CA2974775C CA 2974775 C CA2974775 C CA 2974775C CA 2974775 A CA2974775 A CA 2974775A CA 2974775 A CA2974775 A CA 2974775A CA 2974775 C CA2974775 C CA 2974775C
Authority
CA
Canada
Prior art keywords
protein
expression
pdac
concentration
reg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2974775A
Other languages
English (en)
French (fr)
Other versions
CA2974775A1 (en
Inventor
Tatjana Crnogorac-Jurcevic
Tomasz RADON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary University of London filed Critical Queen Mary University of London
Publication of CA2974775A1 publication Critical patent/CA2974775A1/en
Application granted granted Critical
Publication of CA2974775C publication Critical patent/CA2974775C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Data Mining & Analysis (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2974775A 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer Active CA2974775C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1501930.0 2015-02-05
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer
PCT/GB2016/050277 WO2016124947A1 (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Publications (2)

Publication Number Publication Date
CA2974775A1 CA2974775A1 (en) 2016-08-11
CA2974775C true CA2974775C (en) 2023-11-07

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974775A Active CA2974775C (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Country Status (15)

Country Link
US (3) US10782301B2 (enExample)
EP (2) EP4458849A3 (enExample)
JP (1) JP6786499B2 (enExample)
KR (1) KR102569984B1 (enExample)
CN (1) CN107533062B (enExample)
AU (1) AU2016214140B2 (enExample)
BR (1) BR112017016808A2 (enExample)
CA (1) CA2974775C (enExample)
CL (1) CL2017001972A1 (enExample)
GB (1) GB201501930D0 (enExample)
HK (1) HK1247276A1 (enExample)
IL (1) IL253710B (enExample)
MX (1) MX2017009998A (enExample)
SG (1) SG11201706223VA (enExample)
WO (1) WO2016124947A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2442919T3 (es) 2007-03-27 2014-02-14 Immunovia Ab Firma/marcadores de proteínas para la detección de adenocarcinoma
GB201501930D0 (en) * 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
EP4045912A1 (en) * 2019-10-18 2022-08-24 Reccan Diagnostics AB Apparatuses and methods for detection of pancreatic cancer
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
CN115290732B (zh) * 2022-07-14 2025-02-25 西北大学 一种检测胰蛋白酶的电化学生物传感器及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE60325628D1 (de) 2002-09-30 2009-02-12 Oncotherapy Science Inc Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050095611A1 (en) 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
CA2525740A1 (en) 2003-05-15 2004-11-25 Europroteome Ag Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
CA2595377A1 (en) 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
US20070031867A1 (en) 2005-06-27 2007-02-08 John Wayne Cancer Institute Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
US20070077582A1 (en) 2005-09-16 2007-04-05 Primera Biosystems, Inc. Method for quantitative detection of short RNA molecules
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2375254A1 (en) 2006-02-17 2011-10-12 The Children's Medical Center Corporation Free NGAL as a biomarker for cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2084539A4 (en) 2006-10-03 2010-09-08 Neuren Pharmaceuticals Ltd TREFOIL FACTORS BINDING CONFORMATION-SPECIFIC ANTIBODIES AND METHODS FOR TREATING CANCER DISEASES AND PROLIFERATION DISORDERS THEREWITH
US20100092476A1 (en) 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
CN104195226B (zh) 2007-04-30 2017-01-11 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
EP2568053B1 (en) 2008-05-12 2014-04-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2009147530A2 (en) 2008-06-06 2009-12-10 Neuren Pharmaceuticals Ltd Conformation specific antibodies that bind trefoil factors
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
CN102725000B (zh) 2010-01-19 2015-10-07 免疫医疗公司 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2012100339A1 (en) 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013043644A1 (en) 2011-09-21 2013-03-28 The University Of North Carolina At Chapel Hill Methods using liver disease biomarkers
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
US20150018235A1 (en) 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
US20150011414A1 (en) 2012-01-16 2015-01-08 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) * 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Also Published As

Publication number Publication date
SG11201706223VA (en) 2017-08-30
US20250251399A1 (en) 2025-08-07
US10782301B2 (en) 2020-09-22
EP3254111A1 (en) 2017-12-13
GB201501930D0 (en) 2015-03-25
AU2016214140B2 (en) 2021-11-04
CL2017001972A1 (es) 2018-03-23
US20190204323A1 (en) 2019-07-04
KR102569984B1 (ko) 2023-08-22
AU2016214140A1 (en) 2017-08-17
EP4458849A3 (en) 2024-12-04
CA2974775A1 (en) 2016-08-11
BR112017016808A2 (pt) 2018-04-03
MX2017009998A (es) 2018-02-01
KR20170129118A (ko) 2017-11-24
IL253710B (en) 2020-08-31
CN107533062B (zh) 2021-03-23
US20220042998A1 (en) 2022-02-10
US11977077B2 (en) 2024-05-07
EP4458849A2 (en) 2024-11-06
WO2016124947A1 (en) 2016-08-11
JP6786499B2 (ja) 2020-11-18
HK1247276A1 (zh) 2018-09-21
JP2018504609A (ja) 2018-02-15
IL253710A0 (en) 2017-09-28
CN107533062A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
US20250251399A1 (en) Biomarkers for pancreatic cancer
EP4045912A1 (en) Apparatuses and methods for detection of pancreatic cancer
US20140274794A1 (en) Methods and Compositions for Diagnosis of Ovarian Cancer
US10338076B2 (en) Methods and compositions for the diagnosis of ovarian cancer
CA2815356A1 (en) Lung cancer tests
ES2953011T3 (es) Agrina como marcador de cáncer de endometrio
KR20180036787A (ko) 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
WO2019115679A1 (en) A signature to assess prognosis and therapeutic regimen in liver cancer
EP4237090A1 (en) Methods for the detection and treatment of ovarian cancer
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
CN115372616A (zh) 胃癌相关的生物标志物及其应用
HK40118234A (en) Biomarkers for pancreatic cancer
CN116413430B (zh) 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒
US10866239B2 (en) Methods for colon hyperproliferative disorder detection, prognosis, and diagnosis
CN110687284A (zh) 检测血清中six2自身抗体的试剂的应用
WO2010017331A1 (en) Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
EP2963124B1 (en) Biomarker combinations for use in pancreatic cancer screening

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204

EEER Examination request

Effective date: 20210204